Opioid-dependent patients treated at an emergency department (ED) who were given buprenorphine were more likely to engage in addiction treatment to reduce their opioid use, according to a study published in JAMA.
Opioid-dependent patients treated at an emergency department (ED) who were given buprenorphine were more likely to engage in addiction treatment to reduce their opioid use, according to a study published in JAMA.
The researchers randomized patients into 3 groups: the referral group (104 patients), the brief intervention group (111 patients), and the buprenorphine treatment group (114 patients). They then tested the efficacy of these 3 interventions
“Opioid dependence and overdose is an escalating problem that has really reached epidemic proportions here in the US,” Gail D’Onofrio, MD, first author and chair of emergency medicine at Yale School of Medicine, said in a video interview with JAMA. “The emergency department is often the place where patients with opioid dependence seek their care, so it makes sense that this would be the place where we would try to screen and intervene for this very significant problem.”
The patients who were in the buprenorphine treatment group showed a significant increase in engagement in addiction treatment compared to patients in the brief intervention and referral groups. ED-initiated buprenorphine also reduced self-reported illicit opioid use.
“Buprenorphine does require special training and a waiver from the FDA in order to prescribe it, which does set up some barriers,” Dr D’Onofrio said.
More than three-fourths (78%) of the buprenorphine group was engaged in treatment by the end of the 30 days compared with 37% and 45% of the referral and brief intervention groups, respectively. In addition the mean number of days of illicit opioid use per week was down to 0.9 days from 5.4 days in the buprenorphine group compared with 2.3 days from 54 in the referral group and 2.4 days from 5.6 in the brief intervention group.
However, across treatment groups there was little difference in the rate of opioid negative urine toxicology test results.
The researchers also reported that patients in the buprenorphine group were less likely to use inpatient addiction treatment services, which suggests that the treatment may be more efficient and less costly.
“Effectively linking ED-initiated buprenorphine treatment to ongoing treatment in primary care represents an exciting new model for engaging patients who are dependent on opioids into state-of-the-art care,” Patrick G. O’Connor, MD, MPH, FACP, professor of medicine and chief of general internal medicine at Yale School of Medicine and study co-author, said in a statement.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More